KERX could possibly reach $16 this week or next due to the conference and coverage....
as at least 2 price targets have been increased with more to come, and the analysts covering the pharma companies at the conference will get a real sense of the responses of the attendees and may find out that the post-FDA approval penetration numbers could be much greater than previously forecast----MUCH HIGHER. Throw in more short covering and a little more squeezing and the stock still has plenty of room to run. Holding on to every share nd will pick up more on any pullback after all of this great news.
MGM, slope of the channel is forming right now as the week unfolds. If you compare the channel slope from the very defined one a few weeks back it seems parallel. This time no Government interruption. What do you think the analysts have included in their $26 to $28 price targets?? All the way through US approval or just Japan? Thoughts. How could thin be verified short of calling them and asking them.
Most firms typically issue their price targets as 12 months targets unless otherwise stated, I believe. So that would take the stock to and just beyond US approval--but it does indicate that all of the firms strongly believe the FDA will approve Zerenex, and at least Brean and Roth have increased their estimates factoring in a larger contribution from PDKD---but even those estimates seem a bit conservative. It does appear that the stock will climb a bit more and establish a higher base, which it should following the P2 results indicating a much larger global market for the drug. The overall picture for Zerenex has been ratcheted up a few notches.